GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Net Cash per Share

Mallinckrodt (Mallinckrodt) Net Cash per Share : $-411.99 (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Mallinckrodt's Net Cash per Share for the quarter that ended in Sep. 2023 was $-411.99.

The historical rank and industry rank for Mallinckrodt's Net Cash per Share or its related term are showing as below:

MCKPF's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.76
* Ranked among companies with meaningful Price-to-Net-Cash only.

Mallinckrodt Net Cash per Share Historical Data

The historical data trend for Mallinckrodt's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Net Cash per Share Chart

Mallinckrodt Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -91.70 -90.45 -90.13 -85.66 -302.99

Mallinckrodt Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -305.00 -302.99 -298.11 -301.06 -411.99

Competitive Comparison of Mallinckrodt's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mallinckrodt's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's Price-to-Net-Cash falls into.



Mallinckrodt Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Mallinckrodt's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(409.5-4400.1-0)/13.1709
=-302.99

Mallinckrodt's Net Cash per Share for the quarter that ended in Sep. 2023 is calculated as

Net Cash per Share (Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(389.8-5892.9-0)/13.3573
=-411.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mallinckrodt  (OTCPK:MCKPF) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Mallinckrodt Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Mallinckrodt (Mallinckrodt) Business Description

Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
Alta Fundamental Advisers Llc 10 percent owner 1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson officer: EVP & Head of Corp Development 106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat director
Paul Bisaro director
Sigurdur O Olafsson director, officer: President and CEO 360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch officer: EVP & Head of Spec Generics 18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson officer: EVP & Chief Scientific Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French officer: EVP & Chief Commercial Officer 301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall officer: EVP & Chief Legal Offi & Secre 1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen officer: EVP & Chief Transformation OFC 202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF

Mallinckrodt (Mallinckrodt) Headlines

From GuruFocus